NKG mice (Catalog Number: C001316) are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced complement activity, and weak macrophage phagocytosis of human cells. As a result, NKG mice can efficiently engraft human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), patient-derived xenografts (PDX), or adult stem cells and tissues. Interleukin-15 (IL-15) is a cytokine that regulates the activation and proliferation of T cells and natural killer (NK) cells. It also plays a role in balancing the number of CD8+ memory cells alongside IL-2. Research indicates that IL-15 is essential for the differentiation, function, and survival of NK cells. Providing sufficient human IL-15 can help stabilize the function of human NK cells within a mouse model ^[1-2]. The NKG-hIL15 mice (Catalog Number: C001513) are constructed by knocking in the human IL15 gene from the NKG mice. Compared to NKG mice, NKG-hIL15 mice significantly enhance the reconstitution proportion of human NK cells after HSC or PBMC transplantation. These mice can be utilized for the development of immunotherapies targeting NK cells and drug evaluation. The huHSC-NKG-hIL15 mouse refers to an immune system humanized mouse model constructed by transplanting human hematopoietic stem cells (HSC) into NKG-hIL15 mice after sub-lethal dose irradiation. This model can reconstitute various immune cells, has a long lifespan, and is particularly effective in rebuilding human NK cells, which can aid in the development of NK cell-related tumor immunotherapies.

NKG mice (Product number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX) to obtain the humanized mice with the human immune system. PBMC humanized mice refer to the immune system humanized mouse model constructed by transplanting human peripheral blood mononuclear cells (PBMC) into immunodeficient mice (such as NKG). NKG mice transplanted with PBMC (huPBMC-NKG) have high efficiency and fast immune reconstitution. The average proportion of human CD45+ in peripheral blood (PB) is about 50% after 3 weeks of transplantation, and the reconstituted immune cells are mainly lymphoid T cells. Human T cells generated after PBMC injection will attack mouse recipient cells, resulting in graft-versus-host disease (GvHD), so this model can be used to evaluate GvHD drugs.

NKG mice (catalog number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX). huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute a variety of immune cells. Furthermore, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be lengthy.

NKG mice (Catalog number: C001316) are severely immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenografts (PDX). huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute various immune cells. In addition, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be long. The huHSC-NKG-ProN mouse is the latest enhanced version of the huHSC-NKG series, where "Pro" indicates the enhanced series and "N" specifically refers to NK cells (Natural Killer cells). This mouse utilizes advanced neonate technology and has been process-optimized to allow for the development of lymphoid T cells and B cells, as well as NK cells, with minimal myeloid development. It is suitable for research on immune checkpoint inhibitors, ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) mechanisms, and in vivo CAR-NK cell therapy.

NKG mice (Catalog number: C001316) are severely immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenografts (PDX). huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute various immune cells. In addition, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be long. The huHSC-NKG-ProM mouse is the latest enhanced version of the huHSC-NKG series, where "Pro" indicates the enhanced series and "M" specifically refers to myeloid cells. This mouse utilizes advanced neonate technology and has been process-optimized to allow for the development of lymphoid T cells and B cells, as well as myeloid cells such as monocytes. It is suitable for research on immune checkpoint inhibitors and drugs that target myeloid cells.

NKG mice (Catalog number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX). huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute various immune cells. In addition, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be long. The huHSC-NKG-ProF mouse is the latest enhanced version of the huHSC-NKG series, where "Pro" indicates the enhanced series and "F" indicates full immune reconstitution. This mouse model uses advanced neonatal techniques optimised to develop a variety of human immune cells, including lymphoid T cells, B cells and NK cells, as well as myeloid dendritic cells (DCs), monocytes, macrophages and granulocytes. Due to its ability to reconstitute multiple types of human-derived immune cells, the huHSC-NKG-ProF mouse is also referred to as a fully humanised immune system mouse. It is an ideal model for immunological research, antibody-dependent cellular cytotoxicity (ADCC) studies and the development of tumor vaccines, cellular therapies and other biopharmaceuticals.